Clinical trials: Severe Ulcerative Colitis
- Condition Severe Ulcerative Colitis
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Ulcerative Colitis (UC)
A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis
The goal of this clinical trial is to learn if BB-TL1A-VIAL-HLE is safe in healthy adults and is safe and effective in treating adults with moderate-to-severe ulcerative colitis.
- Trial name
- NCT07029971
- Testing
- BB-TL1A-VIAL-HLE
- Where
- 2 sites in Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vial Australia Pty Ltd
Multiple Sclerosis, Ulcerative Colitis
Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects
The goal of this clinical trial is to learn how Ozanimod drug can be administered to the healthy subjects via transdermal delivery system (TDS, patch) to achieve better drug absorption and delivery than via oral capsules…
- Trial name
- NCT06528665
- Testing
- ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults
- Where
- Malaysia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Corium Innovations, Inc.
Moderate-to-severe Inflammatory Bowel Disease
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease
This Phase I first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-7590 via subcutaneous or intravenous administration in Chinese healthy participants and patients with…
- Trial name
- NCT07758101
- Testing
- SHR-7590
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy Volunteers, Ulcerative Colitis
Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis
The primary purpose of this study is to determine if single and multiple doses of BMS-986184 are safe and well tolerated in healthy male and female subjects.
- Trial name
- NCT02864264
- Testing
- BMS-986184
- Where
- 3 sites in Australia, Georgia and 1 more
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis (UC)
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B).
- Trial name
- NCT06619990
- Testing
- XmAb942
- Where
- 114 sites in United States, Argentina and 17 more
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Colitis, Ulcerative, Crohn Disease
Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
The purpose of this study is to evaluate in a step-wise approach the disease drug-drug interaction (DDI) potential for vedolizumab to indirectly affect the exposure of cytochrome P-450 (CYP) substrate drugs by modulating…
- Trial name
- NCT02760615
- Testing
- Caffeine, Losartan, Omeprazole
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Takeda
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Ulcerative Colitis
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis
SOR102-101 is a Phase 1, 3-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of SOR102 (Part 1) and multiple oral doses (Part 2) of…
- Trial name
- NCT06080048
- Testing
- SOR102
- Where
- 2 sites in Georgia, Ukraine
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Sorriso Pharmaceuticals, Inc.